BETWEEN SCYLLA AND CHARYBDIS: COVID-19 AND CANCER (LITERATURE REVIEW)

Keywords: COVID-19, cancer, practical guidelines

Abstract

The global spread of an infectious disease called COVID-19 which is caused by SARS-CoV-2. continues. The adverse course of COVID-19 is most often observed in patients with comorbidities, in particular malignant tumours. The application of active antineoplastic therapy (chemotherapy, immunotherapy, radiation exposure) can have a negative effect on the course of COVID-19. Therefore, systemic cancer treatment must account for the risk/benefit ratio. For each cancer patient, several factors, including age and comorbidities, and even the need to visit a hospital, may increase this risk. It is recommended to consider several variables, including the degree of the epidemic, capacities of local healthcare structures, the risk of patient's infection, the activity of malignancy, patient comorbidities, age, and treatment peculiarities. There are no simple and universal recommendations for providing cancer care during a crisis, and the inability to estimate the pandemic duration aggravates the issue. This literature review analyzes the experience of oncologists from different countries concerning diagnostic and therapeutic tactics for cancer patients during the pandemic. Practical recommendations on various types of tumours and treatment methods, determining priorities in the operation of oncological facilities, and rational use of financial and professional resources are considered.

Downloads

Download data is not yet available.

References

Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506. https://doi.org/10.1016/S0140-6736(20)30183-5

Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. N Engl J Med. 2020;382(13):1199-1207. https://doi.org/10.1056/NEJMoa2001316 PMid:31995857 PMCid:PMC7121484

Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507-513. https://doi.org/10.1016/S0140-6736(20)30211-7

Wang C, Horby PW, Hayden FG, Gao GF. A novel coronavirus outbreak of global health concern. Lancet 2020; published online Jan 24. https://doi.org/10.1016/S0140-6736(20)30185-9

Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W,et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020;579(7798):270-273. https://doi.org/10.1038/s41586-020-2012-7 PMid:32015507 PMCid:PMC7095418

Xia Y, Jin R, Zhao J, Li W, Shen H. Risk of COVID-19 for patients with cancer. Lancet Oncol. 2020 Apr;21(4):e180. https://doi.org/10.1016/S1470-2045(20)30150-9

Liang W, Guan W, Chen R, Wang W, Li J, Xu K, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol 2020; 21(3): 335-337. https://doi.org/10.1016/S1470-2045(20)30096-6

Zhang L, Zhu F, Xie L, Wang C, Wang J, Chen R, et al. Clinical characteristics of COVID-19-infected cancer patients: A retrospective case study in three hospitals within Wuhan, China. Ann Oncol. 2020 Mar 26. pii: S0923 7534(20)36383-3. doi: 10.1016/j.annonc.2020.03.296. [Epub ahead of print]) https://doi.org/10.1016/j.annonc.2020.03.296

Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020 Feb 24. doi: 10.1001/jama.2020.2648. [Epub ahead of print] https://doi.org/10.1001/jama.2020.2648 PMid:32091533

https://www.facebook.com/phc.org.ua/posts/1825959457528774

Banna G, Curioni-Fontecedro A, Friedlaender A, Addeo A. How we treat patients with lung cancer during the SARS-CoV-2 pandemic: primum non nocere. ESMO Open. 2020 Apr;5(2). pii: e000765. doi: 10.1136/esmoopen-2020-000765. https://doi.org/10.1136/esmoopen-2020-000765 PMid:32245904

Cortiula F, Pettke A, Bartoletti M, Puglisi F, Helleday T. Managing COVID-19 in the oncology clinic and avoiding the distraction effect. Ann Oncol. 2020 Mar 19. pii: S0923-7534(20)36373-0. doi: 10.1016/j.annonc.2020.03.286. [Epub ahead of print] https://doi.org/10.1016/j.annonc.2020.03.286 PMid:32201224 PMCid:PMC7174827

You B, Ravaud A, Canivet A, Ganem G, Giraud P, Guimbaud R, et al. The official French guidelines to protect patients with cancer against SARS-CoV-2 infection. Lancet Oncol. 2020 Mar 25. pii: S1470-2045(20)30204-7. doi: 10.1016/S1470-2045(20)30204-7. https://doi.org/10.1016/S1470-2045(20)30204-7

Lambertini M, Toss A, Passaro A, Criscitiello C, Cremolini C, Cardone C, et al. Cancer care during the spread of coronavirus disease 2019 (COVID-19) in Italy: young oncologists' perspective. ESMO Open. 2020 Mar;5(2). pii: e000759. https://doi.org/10.1136/esmoopen-2020-000759 PMid:32229501 PMCid:PMC7174009

Hanna TP, Evans GA, Booth CM. Cancer, COVID-19 and the precautionary principle: prioritizing treatment during a global pandemic. Nat Rev Clin Oncol. 2020 Apr 2. doi: 10.1038/s41571-020-0362-6. [Epub ahead of print]) https://doi.org/10.1038/s41571-020-0362-6 PMid:32242095 PMCid:PMC7117554

Ramirez PT, Chiva L, Eriksson AGZ, Frumovitz M, Fagotti A, Gonzalez Martin A, et al. COVID-19 Global Pandemic: Options for Management of Gynecologic Cancers. Int J Gynecol Cancer. 2020 Mar 27. pii: ijgc-2020-001419. doi: 10.1136/ijgc-2020-001419. [Epub ahead of print] https://doi.org/10.1136/ijgc-2020-001419 PMid:32221023

Coles CE, Aristei C, Bliss J, Boersma L, Brunt AM, Chatterjee S, et al. International Guidelines on Radiation Therapy for Breast Cancer During the COVID-19 Pandemic. Clin Oncol (R Coll Radiol). 2020;32(5):279-281. https://doi.org/10.1016/j.clon.2020.03.006 PMid:32241520

Bonomi L, Ghilardi L, Arnoldi E, Tondini CA, Bettini AC. A rapid fatal evolution of Coronavirus Disease-19 (COVID-19) in an advanced lung cancer patient with a long time response to nivolumab. J Thorac Oncol. 2020 Mar 31. pii: S1556-0864(20)30285-9. https://doi.org/10.1016/j.jtho.2020.03.021 PMid:32243919

Bersanelli M. Controversies about COVID-19 and anticancer treatment with immune checkpoint inhibitors. Immunotherapy. 2020 Mar 26. doi: 10.2217/imt-2020-0067. [Epub ahead of print] https://doi.org/10.2217/imt-2020-0067 PMid:32212881 PMCid:PMC7117596

Shuman AG, Pentz RD. Cancer Research Ethics and COVID-19. Oncologist. 2020 Mar 30. doi: 10.1634/theoncologist.2020-0221. [Epub ahead of print] https://doi.org/10.1634/theoncologist.2020-0221 PMCid:PMC7160395

The Lancet Oncology. COVID-19: global consequences for oncology. Lancet Oncol. 2020;21(4):467. https://doi.org/10.1016/S1470-2045(20)30175-3


Abstract views: 82
PDF Downloads: 50
Published
2020-04-14
How to Cite
1.
Shparyk Y. BETWEEN SCYLLA AND CHARYBDIS: COVID-19 AND CANCER (LITERATURE REVIEW). Proc Shevchenko Sci Soc Med Sci [Internet]. 2020Apr.14 [cited 2020Aug.15];59(1). Available from: https://mspsss.org.ua/index.php/journal/article/view/256